摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-Acetyl-3-[4-[4-(4-fluorophenyl)piperazin-1-yl]butyl]-1,3-benzoxazol-2-one | 1121931-34-7

中文名称
——
中文别名
——
英文名称
5-Acetyl-3-[4-[4-(4-fluorophenyl)piperazin-1-yl]butyl]-1,3-benzoxazol-2-one
英文别名
——
5-Acetyl-3-[4-[4-(4-fluorophenyl)piperazin-1-yl]butyl]-1,3-benzoxazol-2-one化学式
CAS
1121931-34-7
化学式
C23H26FN3O3
mdl
——
分子量
411.476
InChiKey
NIKCPKNTCKAENL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    30
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    53.1
  • 氢给体数:
    0
  • 氢受体数:
    6

文献信息

  • HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS AND RADIOLIGANDS AS PROBES IN NOCICEPTIVE PROCESSING AND THE PATHPHYSIOLOGICAL STUDY OF MEMORY DEFICITS AND COGNITIVE DISORDERS
    申请人:The Board of Trustees of the Leland Stanford Junior University
    公开号:US20140328755A1
    公开(公告)日:2014-11-06
    A method for localizing and quantifying S1R role in nociceptive processing; for providing a guide to providing an analgesic therapy; of using an S1R selective ligand as a biomarker for pathphysiological study of memory deficits and cognitive disorders; or of detecting increased S1R density at the site of nerve injury arising from neuropathic pain comprising using as a probe at least one SR1 selective compound or radioligand of the general formula III′, or IV′:
    一种定位和量化S1R在伤害处理中的作用的方法;为提供镇痛疗法提供指导;使用S1R选择性配体作为记忆缺陷和认知障碍的病理生理研究的生物标志物;或者使用至少一种SR1选择性化合物或放射性配体作为探针,检测神经病理性疼痛引起的神经损伤部位的S1R密度增加,其化学结构为通式III'或IV'。
  • HIGHLY SELECTIVE SIGMA 1 RECEPTOR LIGANDS AND RADIOLIGANDS AS PROBES IN NOCICEPTIVE PROCESSING AND THE PATHOPHYSIOLOGICAL STUDY OF MEMORY DEFICITS AND COGNITIVE DISORDERS
    申请人:The University Of Mississippi
    公开号:EP3102204B1
    公开(公告)日:2021-05-05
  • HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS
    申请人:McCurdy Christopher R.
    公开号:US20100329978A1
    公开(公告)日:2010-12-30
    Compounds having the general formula II, III, or IV wherein R 1 can be a radical of an optionally substituted C-4 to C-7 N-containing heterocycle or a radical of an optionally substituted cyclic or acyclic tertiary amine or isoindoline-1,3-dione: R 2,3,4,5,6 can each independently be any one or combinations of the following moieties, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate, optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; Y can be either CH, CH 2 , O, S, OCH 2 , N—R, N—Ar, C—R, C—Ar; Z can be either H, O, S, S—R or NR. R groups can be either H, aryls, alkyls, or cycloalkyls; “n” can be 1 to 5 carbons in length and stereoisomers, functional analogs, and pharmaceutically acceptable salts thereof and wherein the moiety bridging R 1 and N can be a substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene and where the alkylene group can include an inserted C 3 -C 5 cycloalkyl group, aromatic, and hetercocyclic group; wherein X′ is halogen, or C 1 -C 4 haloalyl; wherein the R x is a C 1 -C 5 straight chain or branched chain alkyl or a C 1 -C 4 straight chain or branched chain haloalkyl.
  • US8809381B2
    申请人:——
    公开号:US8809381B2
    公开(公告)日:2014-08-19
  • US9724435B2
    申请人:——
    公开号:US9724435B2
    公开(公告)日:2017-08-08
查看更多